Andromeda Robotics raised $17 million to expand its ChatGPT-enabled companion robot Abi into US senior living facilities, part of a broader push to use AI robots to ease a worsening eldercare staffing shortage.
Mind's new research found 60% of people who used AI chatbots for mental health support in the past year did so instead of formal care like NHS talking therapies, as AI-related safeguarding concerns hit nearly 10% of all cases.
A JAMA Network Open study of nearly 1,565 physicians found AI scribe adopters generated 1.81 more RVUs per week and about $3,044 more annual revenue than non-adopters, with no increase in claim denials.
A JMIR Mental Health pilot trial found only 39% of users completed a purpose-built AI therapy chatbot program, versus 62% who stuck with plain ChatGPT, raising new questions about engagement in AI mental-health tools.
A Harvard-linked analysis of physician queries to the clinical AI tool OpenEvidence found doctors mainly use AI to inform treatment and management decisions rather than diagnosis, a pattern mirrored in how Epic and Doximity are building their own clinical AI tools.
The American Hospital Association urged the FDA to adopt flexible, risk-based oversight of generative AI medical tools as the agency's comment period on its discussion paper closed October 19, with patient-safety advocates pushing for firmer rules instead.
The FDA's comment period on regulating generative AI medical devices closed October 19, with the American Hospital Association pushing for a risk-based framework as the agency works toward formal 2027 guidance covering AI in mental health and surgery.
Optellum's lung cancer risk AI, the first both FDA-cleared and Medicare-reimbursed tool of its kind, is now integrated into RapidAI's platform, a combination that could meaningfully speed adoption compared to AI tools lacking payer coverage.
FDA-cleared AI tool TumorSight Risk uses a patient's existing breast MRI to predict cancer recurrence risk without added scans, joining a growing wave of cleared cancer-imaging AI tools even as researchers push for outcomes data beyond accuracy.
Billions have poured into AI drug discovery deals, but no AI-discovered drug has yet won full FDA approval — a gap that will test whether the technology's promise translates into real medicines.